Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine.

Murray JL, Mercer SL, Jackson KD.

Xenobiotica. 2019 Mar 22:1-14. doi: 10.1080/00498254.2019.1599465. [Epub ahead of print]

PMID:
30902024
2.

A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β.

Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC Jr, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B.

Invest New Drugs. 2018 Dec;36(6):1103-1109. doi: 10.1007/s10637-018-0672-z. Epub 2018 Oct 11.

PMID:
30311036
3.

Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.

Jackson DO, Trappey FA, Clifton GT, Vreeland TJ, Peace KM, Hale DF, Litton JK, Murray JL, Perez SA, Papamichail M, Mittendorf EA, Peoples GE.

Clin Immunol. 2018 Oct;195:28-35. doi: 10.1016/j.clim.2018.06.008. Epub 2018 Jul 17.

PMID:
30025819
4.

Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.

Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT.

JAMA Oncol. 2018 Sep 1;4(9):1207-1213. doi: 10.1001/jamaoncol.2018.1436.

5.

Moving epidemic method (MEM) applied to virology data as a novel real time tool to predict peak in seasonal influenza healthcare utilisation. The Scottish experience of the 2017/18 season to date.

Murray JLK, Marques DFP, Cameron RL, Potts A, Bishop J, von Wissmann B, William N, Reynolds AJ, Robertson C, McMenamin J.

Euro Surveill. 2018 Mar;23(11). doi: 10.2807/1560-7917.ES.2018.23.11.18-00079.

6.

A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.

Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B.

Invest New Drugs. 2018 Apr;36(2):299-306. doi: 10.1007/s10637-018-0564-2. Epub 2018 Jan 27.

PMID:
29374384
7.

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.

Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL 3rd, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL.

JAMA Oncol. 2017 Apr 1;3(4):509-515. doi: 10.1001/jamaoncol.2016.5281.

PMID:
27893038
8.

Drug Repurposing: New Treatments for Zika Virus Infection?

Cheng F, Murray JL, Rubin DH.

Trends Mol Med. 2016 Nov;22(11):919-921. doi: 10.1016/j.molmed.2016.09.006. Epub 2016 Sep 28.

PMID:
27692879
9.

Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional Mutagenesis.

Cheng F, Murray JL, Zhao J, Sheng J, Zhao Z, Rubin DH.

PLoS Comput Biol. 2016 Sep 15;12(9):e1005074. doi: 10.1371/journal.pcbi.1005074. eCollection 2016 Sep.

10.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.

Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, Perez SA, Ponniah S, Baxevanis CN, Papamichail M, Peoples GE.

Oncotarget. 2016 Oct 4;7(40):66192-66201. doi: 10.18632/oncotarget.11751.

11.

Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer.

Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N.

Breast Cancer Res Treat. 2016 Jul;158(1):67-77. doi: 10.1007/s10549-016-3849-1. Epub 2016 Jun 10.

12.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.

Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE.

Ann Oncol. 2016 Jul;27(7):1241-8. doi: 10.1093/annonc/mdw150. Epub 2016 Mar 30.

13.

Intrinsic Antimicrobial Resistance Determinants in the Superbug Pseudomonas aeruginosa.

Murray JL, Kwon T, Marcotte EM, Whiteley M.

MBio. 2015 Oct 27;6(6):e01603-15. doi: 10.1128/mBio.01603-15.

14.

Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.

Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, Madan RA, McMahon S, Marté JL, Steinberg SM, Donahue RN, Grenga I, Jochems C, Farsaci B, Folio LR, Schlom J, Gulley JL.

JAMA Oncol. 2015 Nov;1(8):1087-95. doi: 10.1001/jamaoncol.2015.2736. Erratum in: JAMA Oncol. 2015 Nov;1(8):1171-2.

15.

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.

Mitri Z, Karakas C, Wei C, Briones B, Simmons H, Ibrahim N, Alvarez R, Murray JL, Keyomarsi K, Moulder S.

Invest New Drugs. 2015 Aug;33(4):890-4. doi: 10.1007/s10637-015-0244-4. Epub 2015 May 7.

PMID:
25947565
16.

Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.

Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F.

Clin Breast Cancer. 2015 Oct;15(5):325-31. doi: 10.1016/j.clbc.2015.03.004. Epub 2015 Mar 24.

17.

Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum.

Turner KH, Wessel AK, Palmer GC, Murray JL, Whiteley M.

Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):4110-5. doi: 10.1073/pnas.1419677112. Epub 2015 Mar 16.

18.

Characteristics and intraoperative treatments associated with head and neck free tissue transfer complications and failures.

Hand WR, McSwain JR, McEvoy MD, Wolf B, Algendy AA, Parks MD, Murray JL, Reeves ST.

Otolaryngol Head Neck Surg. 2015 Mar;152(3):480-7. doi: 10.1177/0194599814564366. Epub 2014 Dec 30.

19.

Seven novel probe systems for real-time PCR provide absolute single-base discrimination, higher signaling, and generic components.

Murray JL, Hu P, Shafer DA.

J Mol Diagn. 2014 Nov;16(6):627-38. doi: 10.1016/j.jmoldx.2014.06.008.

20.

Canine scent detection and microbial source tracking of human waste contamination in storm drains.

Van De Werfhorst LC, Murray JL, Reynolds S, Reynolds K, Holden PA.

Water Environ Res. 2014 Jun;86(6):550-8.

PMID:
25109201
21.

Microbial source tracking in a coastal California watershed reveals canines as controllable sources of fecal contamination.

Ervin JS, Van De Werfhorst LC, Murray JL, Holden PA.

Environ Sci Technol. 2014 Aug 19;48(16):9043-52. doi: 10.1021/es502173s. Epub 2014 Aug 5.

PMID:
25055204
22.

Nuclear trafficking of the HIV-1 pre-integration complex depends on the ADAM10 intracellular domain.

Endsley MA, Somasunderam AD, Li G, Oezguen N, Thiviyanathan V, Murray JL, Rubin DH, Hodge TW, O'Brien WA, Lewis B, Ferguson MR.

Virology. 2014 Apr;454-455:60-6. doi: 10.1016/j.virol.2014.02.006. Epub 2014 Feb 22.

23.

Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature.

Abdayem P, Ghosn M, Valero V, Walters R, Arun B, Murray JL, Theriault R, Frye D, Ibrahim NK.

J Cancer. 2014 Mar 29;5(5):351-9. doi: 10.7150/jca.8304. eCollection 2014.

24.

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.

Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ.

Cancer. 2014 Jul 1;120(13):1932-8. doi: 10.1002/cncr.28689. Epub 2014 Mar 26.

25.

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F.

Ann Oncol. 2014 Jun;25(6):1122-7. doi: 10.1093/annonc/mdu124. Epub 2014 Mar 24.

26.

Mechanisms of synergy in polymicrobial infections.

Murray JL, Connell JL, Stacy A, Turner KH, Whiteley M.

J Microbiol. 2014 Mar;52(3):188-99. doi: 10.1007/s12275-014-4067-3. Epub 2014 Mar 1. Review.

PMID:
24585050
27.

The dual role of tetraspanin CD63 in HIV-1 replication.

Li G, Endsley MA, Somasunderam A, Gbota SL, Mbaka MI, Murray JL, Ferguson MR.

Virol J. 2014 Feb 8;11:23. doi: 10.1186/1743-422X-11-23.

28.

A role for H/ACA and C/D small nucleolar RNAs in viral replication.

Murray JL, Sheng J, Rubin DH.

Mol Biotechnol. 2014 May;56(5):429-37. doi: 10.1007/s12033-013-9730-0.

PMID:
24477674
29.

Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial.

Ibrahim NK, Murray JL, Zhou D, Mittendorf EA, Sample D, Tautchin M, Miles D.

J Cancer. 2013 Aug 22;4(7):577-84. doi: 10.7150/jca.7028. eCollection 2013.

30.

Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer.

Chen JQ, Bao Y, Lee J, Murray JL, Litton JK, Xiao L, Zhou R, Wu Y, Shen XY, Zhang H, Sahin AA, Katz RL, Bondy ML, Berinstein NL, Hortobagyi GN, Radvanyi LG.

Ann Oncol. 2013 Oct;24(10):2534-42. doi: 10.1093/annonc/mdt190. Epub 2013 May 31.

31.

Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer.

Murray JL, Thompson P, Yoo SY, Do KA, Pande M, Zhou R, Liu Y, Sahin AA, Bondy ML, Brewster AM.

Breast Cancer Res Treat. 2013 Apr;138(3):917-24. doi: 10.1007/s10549-013-2445-x. Epub 2013 Mar 26.

32.

Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.

Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN, Yeung SC.

Cancer Chemother Pharmacol. 2013 Jan;71(1):63-72. doi: 10.1007/s00280-012-1977-9. Epub 2012 Sep 28.

33.

Identification of cellular proteins required for replication of human immunodeficiency virus type 1.

Dziuba N, Ferguson MR, O'Brien WA, Sanchez A, Prussia AJ, McDonald NJ, Friedrich BM, Li G, Shaw MW, Sheng J, Hodge TW, Rubin DH, Murray JL.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1329-39. Epub 2012 Apr 20.

34.

Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis.

Murray JL, McDonald NJ, Sheng J, Shaw MW, Hodge TW, Rubin DH, O'Brien WA, Smee DF.

Antivir Chem Chemother. 2012 May 14;22(5):205-15. doi: 10.3851/IMP2080.

PMID:
22374988
35.

Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.

Wu RC, Liu S, Chacon JA, Wu S, Li Y, Sukhumalchandra P, Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi LG.

Clin Cancer Res. 2012 May 1;18(9):2465-77. doi: 10.1158/1078-0432.CCR-11-2034. Epub 2012 Feb 3.

36.

Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.

Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L.

J Clin Oncol. 2012 Mar 1;30(7):729-34. doi: 10.1200/JCO.2011.36.2574. Epub 2012 Jan 30.

PMID:
22291085
37.

A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.

Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT.

Cancer. 2012 May 1;118(9):2378-84. doi: 10.1002/cncr.26571. Epub 2011 Oct 17.

38.

Occurrence of glyphosate and acidic herbicides in select urban rivers and streams in Canada, 2007.

Glozier NE, Struger J, Cessna AJ, Gledhill M, Rondeau M, Ernst WR, Sekela MA, Cagampan SJ, Sverko E, Murphy C, Murray JL, Donald DB.

Environ Sci Pollut Res Int. 2012 Mar;19(3):821-34. doi: 10.1007/s11356-011-0600-7. Epub 2011 Sep 25.

PMID:
21948131
39.

Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer.

Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, Komisarenko V, Shparyk Y, Murray JL, Jones D, Senderovich S, Chau A, Erlandsson F, Acton G, Pegram M.

Clin Cancer Res. 2011 Nov 1;17(21):6822-30. doi: 10.1158/1078-0432.CCR-11-1151. Epub 2011 Aug 30.

40.

Host factors mediating HIV-1 replication.

Friedrich BM, Dziuba N, Li G, Endsley MA, Murray JL, Ferguson MR.

Virus Res. 2011 Nov;161(2):101-14. doi: 10.1016/j.virusres.2011.08.001. Epub 2011 Aug 18. Review.

PMID:
21871504
41.

Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer.

Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, Hahn KM, Murray JL, Sahin A, Tsavachidis S, Wang Y, Zhang L, Hortobagyi GN, Mills GB, Bondy ML.

PLoS One. 2011;6(8):e23543. doi: 10.1371/journal.pone.0023543. Epub 2011 Aug 12.

42.

Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival.

Brewster AM, Thompson P, Sahin AA, Do K, Edgerton M, Murray JL, Tsavachidis S, Zhou R, Liu Y, Zhang L, Mills G, Bondy M.

Cancer Prev Res (Phila). 2011 Oct;4(10):1609-16. doi: 10.1158/1940-6207.CAPR-10-0361. Epub 2011 Jul 27.

43.

Sewage exfiltration as a source of storm drain contamination during dry weather in urban watersheds.

Sercu B, Van De Werfhorst LC, Murray JL, Holden PA.

Environ Sci Technol. 2011 Sep 1;45(17):7151-7. doi: 10.1021/es200981k. Epub 2011 Aug 10.

PMID:
21786744
44.

Application of an integrated community analysis approach for microbial source tracking in a coastal creek.

Cao Y, Van De Werfhorst LC, Sercu B, Murray JL, Holden PA.

Environ Sci Technol. 2011 Sep 1;45(17):7195-201. doi: 10.1021/es201118r. Epub 2011 Aug 16.

PMID:
21786742
45.

Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancer.

Chen JQ, Bao Y, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Wu S, Katz RL, Sahin A, Bondy M, Murray JL, Radvanyi L.

Horm Cancer. 2011 Apr;2(2):132-43. doi: 10.1007/s12672-011-0067-5.

PMID:
21761336
46.

Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials.

Mittendorf EA, Alatrash G, Xiao H, Clifton GT, Murray JL, Peoples GE.

Expert Rev Vaccines. 2011 Jun;10(6):755-74. doi: 10.1586/erv.11.59. Review.

PMID:
21692698
47.

Terrestrial sources homogenize bacterial water quality during rainfall in two urbanized watersheds in Santa Barbara, CA.

Sercu B, Van De Werfhorst LC, Murray JL, Holden PA.

Microb Ecol. 2011 Oct;62(3):574-83. doi: 10.1007/s00248-011-9874-z. Epub 2011 May 27. Erratum in: Microb Ecol. 2011 Jul;62(1):238-9.

PMID:
21617896
48.

Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.

Miles D, Roché H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, Murray JL, Ibrahim NK; Theratope® Study Group.

Oncologist. 2011;16(8):1092-100. doi: 10.1634/theoncologist.2010-0307. Epub 2011 May 14.

49.

A functional role for ADAM10 in human immunodeficiency virus type-1 replication.

Friedrich BM, Murray JL, Li G, Sheng J, Hodge TW, Rubin DH, O'Brien WA, Ferguson MR.

Retrovirology. 2011 May 11;8:32. doi: 10.1186/1742-4690-8-32.

50.

A post-entry role for CD63 in early HIV-1 replication.

Li G, Dziuba N, Friedrich B, Murray JL, Ferguson MR.

Virology. 2011 Apr 10;412(2):315-24. doi: 10.1016/j.virol.2011.01.017. Epub 2011 Feb 26.

Supplemental Content

Loading ...
Support Center